PI3K-Akt/mTOR経路を阻害することによって,腫瘍免疫微環境におけるDDIT4の関与のレビュー
PubMedで要約を見る
まとめ
この要約は機械生成です。DNAダメージ誘導性トランスクリプト4 (DDIT4) は,PI3K- Akt/ mTOR経路を阻害することによって,がん免疫に影響を与えます. このレビューは,DDIT4について考察します.
科学分野
- 分子生物学
- 癌 研究
- 免疫学
背景
- DNAダメージ誘導性トランスクリプト4 (DDIT4) は,細胞ストレス中に上調されるPI3K- Akt/ mTOR経路の既知の阻害剤である.
- DDIT4の発現の上昇は,様々な癌で観察され,腫瘍の促進または抑制における文脈に依存する役割があります.
- 腫瘍免疫調節へのDDIT4の関与の正確なメカニズムは完全に理解されていません.
研究 の 目的
- DDIT4が腫瘍免疫を調節するメカニズムを体系的に検討する.
- 腫瘍免疫微環境 (TME) に及ぼすDDIT4の影響を調べる.
- 免疫療法の標的としてDDIT4の基礎を提供すること.
主な方法
- DDITに関する既存の研究の体系的な文献レビューと合成4.
- PI3K-Akt/mTOR経路を調節するDDIT4の役割の分析
- TME内の自己消化,代謝再プログラム,免疫細胞機能に対するDDIT4の効果の検討.
主要な成果
- DDIT4はPI3K-Akt/mTOR経路を阻害し,オートファギーの活性化と代謝の再プログラムにつながります.
- DDIT4は,腫瘍細胞,先天性および適応性免疫細胞,およびサイトカインを含む様々なTME成分に影響を与えます.
- DDIT4は,腫瘍の微小環境内で文脈依存の免疫調節効果を発揮する.
結論
- DDIT4は腫瘍の免疫調節に多面的に重要な役割を果たします.
- DDIT4のメカニズムの理解は,新しいがん免疫療法の開発に不可欠です.
- DDIT4は抗腫瘍免疫を強化する有望な治療標的です.
関連する概念動画
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

